The Precision Peptide Company Inc. (CSE:BPC)
Canada · Delayed Price · Currency is CAD | Market Cap | 19.47M +56.0% |
| Revenue (ttm) | 167.35K +2,292.0% |
| Net Income | -7.12M |
| EPS | -0.17 |
| Shares Out | 55.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,994 |
| Open | 0.3550 |
| Previous Close | 0.3450 |
| Day's Range | 0.3350 - 0.3550 |
| 52-Week Range | 0.1750 - 0.5800 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 3, 2027 |
About CSE:BPC
The Precision Peptide Company Inc. manufactures and distributes plant-based patties and other food products in Canada. The company offers old fashioned ghee; energy gel; and plant-based patty; energy gel products, and munchie mix, as well as custom co-packing, private labelling, product development, and label, design, and regulatory services. It also provides peptide therapies for stress management, gut health, longevity, hair health, skin repair, and sleep health. It distributes its products through its websites, retail outlets, and wholesale ... [Read more]
Financial Performance
In fiscal year 2025, CSE:BPC's revenue was 49,720, an increase of 307.47% compared to the previous year's 12,202. Losses were -4.53 million, 339.0% more than in 2024.
Financial StatementsNews
RETRANSMISSION: The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability Highlights Order placed for 20,000 units...
The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability Highlights Order placed for 20,000 units...
The Precision Peptide Company Expands U.S. Wholesale Program, Opening Distribution of Its Needle-Free Range to Clinics, Med Spas, Gyms and Retailers
A second revenue engine for the Company's U.S.-made, needle-free products, built to put them on the shelves where its customers already train, recover and shop Highlights U.S. wholesale channel now op...
The Precision Peptide Company Announces Grants of RSUs and Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the ...
The Precision Peptide Company to Showcase Its Needle-Free Recovery Patch and Supplement Range at FitExpo Anaheim
Highlights The Company's supplement range, led by The Recovery Patch, will be available for purchase on site at FitExpo Anaheim, August 29 and 30, 2026 A 15% event discount will be available to attend...
The Precision Peptide Company Completes Migration of Amino Innovations Online Store and Customer Base to Company Website
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advance...
The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform
Highlights The Company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery Design...
The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review
Highlights Seven products are now in stock and available to purchase at precisionpeptidecompany.com: BPC, KPV, Ageless, Chill, Blue, Hair and The Recovery Patch The Recovery Patch is the Company's fir...
The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support
Highlights Q3/Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch 2025 research continues to evaluate Thymosin Alpha-1 for immun...
The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List. BPC-157 was the first of seven peptide...
The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch
Highlights The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States. 100% U.S.-compounded peptide products are s...
The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news releas...
The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches
Highlights Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate Patches are manufactured and independently tested in the United States...
The Precision Peptide Company Appoints Certified Peptide Therapist and Integrative Health Coach Diane Stafrace to Advisory Board
Key Highlights:
The Precision Peptide Company's Needle-Free Recovery Patch Featured in Men's Health Magazine
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Achieves LegitScript Healthcare Merchant Certification
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Announces Release of The Human Upgrade with Dave Asprey Episode Featuring Chief Scientific Officer Justin Kirkland
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a n...
The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership
Highlights Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide products Builds...
The Precision Peptide Company Inc. Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that, further to its news releas...
The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States
Highlights Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner Compounding activities under the agreement expected to commence on Monday, June 1, 2026 All peptid...
The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas
Highlights Only peptide company exhibiting at BEYOND 2026, Dave Asprey's flagship biohacking, longevity, and consciousness conference Three immersive days in Austin, Texas — May 27-29, 2026 5,000+ att...
The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches
Highlights Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release Initial commercial release of the BPC-1...
The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)
Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and ...
The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch
Highlights The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products Results support The Precis...